Advances in Duchenne muscular dystrophy gene therapy
Related Experiment Video
Updated: Aug 30, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
Published on: September 14, 2019
Judith C T van Deutekom1, Gert-Jan B van Ommen
1Center for Human and Clinical Genetics, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands. deutekom@lumc.nl
Abstract:
Since the initial characterization of the genetic defect for Duchenne muscular dystrophy, much effort has been expended in attempts to develop a therapy for this devastating childhood disease. Gene therapy was the obvious answer but, initially, the dystrophin gene and its product seemed too large and complex for this approach. However, our increasing knowledge of the organization of the gene and the role of dystrophin in muscle function has indicated ways to manipulate them both. Gene therapy for Duchenne muscular dystrophy now seems to be in reach.
More Related Videos
Related Concept Videos
Gene Therapy
Satellite Stem Cells and Muscular Dystrophy
What is Genetic Engineering?
Microorganisms in Medicine and Therapeutics
iPS Cell Differentiation
Pharmacogenomics: Identification of New Drug Targets

